Christopher Sweeney reports on the IPATential150 trial demonstrating the potential of combining the AKT inhibitor ipatasertib with abiraterone in metastatic castration-resistant prostate cancer patients with PTEN loss.
Men with metastatic castration-resistant prostate cancer who receive ipilimumab after radiotherapy to bone metastases have a significantly better long-term survival rate than those who receive placebo, study findings indicate.
Phase 2 TRITON2 study data suggest that men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 mutation may benefit from treatment with the PARP inhibitor rucaparib.
Starting radiotherapy up to 6 months after androgen deprivation therapy may be feasible for men with intermediate- and high-risk localized prostate cancer, say US researchers who found that overall survival was comparable regardless of the timing of radiotherapy initiation.
The use of chemohormonal therapy before radical prostatectomy does not significantly improve 3-year biochemical recurrence-free survival in men with localized, high-risk prostate cancer, phase 3 trial findings suggest.
Two modelling studies published in The Lancet Oncology show the impact cancer diagnostic delays due to COVID-19 could have in England, with some scenarios suggesting over a 1000 people could die unnecessarily.